Nouscom
- Health & Biotech
- Basel, CH
- Founded 2015
- Private
- nouscom.com
Basel biotech developing a cancer-interception vaccine aimed at preventing cancer in people with Lynch syndrome.
$135MEquity raised in 2025–20262025 — · 2026 $135M · 1 equity round
$135MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. Nouscom was founded in 2015 and raised before 19 Oct 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series DAmount$135MEUR 120MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 5
- M Ventures1
- Revelation Partners1
- Angelini Industries
- European Investment Bank
- Neva SGR
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Dren BioHealth · $350M in 2025–2026Shared: Revelation PartnersSTORM TherapeuticsHealth · $56M in 2025–2026Shared: M VenturesNEURA RoboticsRobotics · $1.5B in 2025–2026Shared: European Investment BankExeinCyber · $351M in 2025–2026Shared: European Investment BankHighLifeHealth · $90M in 2025–2026Shared: European Investment BankMorphotonicsDeep Tech · $44.1M in 2025–2026Shared: European Investment Bank
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Nouscom and its logo are trademarks of their owners, used here for identification only.
